Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 6.91
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.
Data is available to registered users only
Buy
Sell